Silverback Therapeutics (Silverback Therapeutics) Pretax Margin % : % (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Silverback Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Silverback Therapeutics's Pre-Tax Income for the three months ended in Sep. 2022 was $-17.86 Mil. Silverback Therapeutics's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Silverback Therapeutics's pretax margin for the quarter that ended in Sep. 2022 was %.

The historical rank and industry rank for Silverback Therapeutics's Pretax Margin % or its related term are showing as below:

SBTX's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -174.24
* Ranked among companies with meaningful Pretax Margin % only.

Silverback Therapeutics Pretax Margin % Historical Data

The historical data trend for Silverback Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silverback Therapeutics Pretax Margin % Chart

Silverback Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Pretax Margin %

Silverback Therapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Pretax Margin %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Silverback Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Silverback Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silverback Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silverback Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Silverback Therapeutics's Pretax Margin % falls into.

Silverback Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Silverback Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-89.478	/	0
	=	%

Silverback Therapeutics's Pretax Margin for the quarter that ended in Sep. 2022 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-17.864	/	0
	=	%

Silverback Therapeutics (NAS:SBTX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Silverback Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Silverback Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silverback Therapeutics (Silverback Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silverback Therapeutics Inc (NAS:SBTX) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Fairview Avenue N, Suite 600, Seattle, WA, USA, 98109

Website

https://www.silverbacktx.com

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Executives

Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Pratik Shah Living Trust Dated June 15, 2011	10 percent owner	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Rajeev Dadoo	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Sarina Tanimoto	10 percent owner, officer: Chief Medical Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Eric Karas	officer: Chief Commercial Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma	officer: Chief Business Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal	director, 10 percent owner, officer: President and CEO	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017